Odyssey Therapeutics creates precision immunomodulators and oncology medicines for patients with cancer and inflammatory diseases.
Odyssey Therapeutics has raised $25.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in May 2026.
Odyssey Therapeutics's investors include TPG, General Catalyst, Lightspeed Venture Partners, GreatPoint Ventures, Catalio Capital Management.
Odyssey Therapeutics is headquartered in Boston, United States.
Odyssey Therapeutics creates precision immunomodulators and oncology medicines for patients with cancer and inflammatory diseases.
Odyssey Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Odyssey Therapeutics — Funding & Investors." VCBacked, May 8, 2026, https://www.vcbacked.co/company/odyssey-therapeutics-boston. Accessed August 15, 2026.
VCBacked. (2026). Odyssey Therapeutics — Funding & Investors. Retrieved August 15, 2026, from https://www.vcbacked.co/company/odyssey-therapeutics-boston
{{cite web |title=Odyssey Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/odyssey-therapeutics-boston |website=VCBacked |access-date=August 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated